ANAPTYSBIO INC

For the period ended Dec 31, 2023. Filed Mar 11, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 11, 2024

ANAB$48.38+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands)

Common Stock · AdditionalPaid-in Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance, January 1, 2021	27,356	$27	$660,665	$(4)	$(263,957)		$396,731
Issuance of common stock from exercises of options and employee stock purchase plan	291	1	2,563	—	—		2,564
Stock-based compensation	—	—	15,347	—	—		15,347
Comprehensive loss	—	—	—	(418)	—		(418)
Net loss	—	—	—	—	(57,796)		(57,796)
Balance, December 31, 2021	27,647	28	678,575	(422)	(321,753)		356,428
Issuance of common stock from exercises of options and employee stock purchase plan	866	1	11,866	—	—		11,867
Stock-based compensation	—	—	27,356	—	—		27,356
Comprehensive loss	—	—	—	(4,824)	—		(4,824)
Net loss	—	—	—	—	(128,724)		(128,724)
Balance, December 31, 2022	28,513	29	717,797	(5,246)	(450,477)		262,103
Issuance of common stock from exercises of options and employee stock purchase plan	139	—	2,421	—	—		2,421
Issuance of common stock upon vesting of restricted stock units	69	—	—	—	—		—
Repurchases and retirements of common stock	(2,124)	(2)	(50,454)			(50,456)
Stock-based compensation	—	—	33,205	—	—		33,205
Comprehensive income	—	—	—	4,449	—		4,449
Net loss	—	—	—	—	(163,619)		(163,619)
Balance, December 31, 2023	26,597	$27	$702,969	$(797)	$(614,096)		$88,103

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.